Market closed

Amicus Therapeutics/$FOLD

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Amicus Therapeutics

Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.

Ticker

$FOLD
Sector
Health Care
Trading on
NASDAQ

Industry

Biotechnology
Headquarters
Princeton, United States

Employees

517
Website
amicusrx.com

FOLD Metrics

BasicAdvanced
$2.8B
-
-$0.35
0.67
-

$2.8B

0.67

$14.03

$8.79

2.5M

3.152

2.2

243.879

248.655

0.29%

1.16%

-67.09%

5.666

15.42

-74.52

-88.754

32.58%

-41.96%

18.87%

-27.34%

What the Analysts think about FOLD

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Amicus Therapeutics stock.

FOLD Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

FOLD Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

FOLD News

AllArticlesVideos
NCLA Amicus Brief Asks Supreme Court to Keep Unlawful Corporate Transparency Act Enjoined

NCLA Amicus Brief Asks Supreme Court to Keep Unlawful Corporate Transparency Act Enjoined

GlobeNewsWire·2 days ago
3 Oversold Biotech Names

3 Oversold Biotech Names

Seeking Alpha·2 days ago
Amicus Therapeutics Reports Preliminary 2024 Revenue and Provides 2025 Strategic Outlook

Amicus Therapeutics Reports Preliminary 2024 Revenue and Provides 2025 Strategic Outlook

GlobeNewsWire·3 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $FOLD

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Amicus Therapeutics stock?

Amicus Therapeutics (FOLD) has a market cap of $2.8B as of January 15, 2025.

What is the P/E ratio for Amicus Therapeutics stock?

The price to earnings (P/E) ratio for Amicus Therapeutics (FOLD) stock is 0 as of January 15, 2025.

Does Amicus Therapeutics stock pay dividends?

No, Amicus Therapeutics (FOLD) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Amicus Therapeutics dividend payment date?

Amicus Therapeutics (FOLD) stock does not pay dividends to its shareholders.

What is the beta indicator for Amicus Therapeutics?

Amicus Therapeutics (FOLD) has a beta rating of 0.67. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.